Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)
Status:
Completed
Trial end date:
2020-12-04
Target enrollment:
Participant gender:
Summary
The global health emergency created by the rapid spread of the SARS-CoV-2 coronavirus has
pushed healthcare services to face unprecedent challenges to properly manage COVID-19 severe
and critical manifestations affecting a wide population in a short period of time. Clinicians
are committed to do their best with a great uncertainty in this evolving crisis. Off label
use of plenty of drugs has arisen the need for clinical trials to demonstrate their true role
in the therapy. Based in unpublished experiences in China, Italy and Spain, intravenous IL-6
receptor inhibitors are now being tested in several trials but no data on subcutaneous
formulations are available yet. Sarilumab is a human monoclonal antibody that binds
membrane-bound and soluble IL-6 receptors to inhibit IL-6 signalling, licensed in a
subcutaneous route administration.
Phase:
Phase 2
Details
Lead Sponsor:
Maria del Rosario Garcia de Vicuña Pinedo
Collaborator:
Instituto de Investigación Sanitaria Hospital Universitario de la Princesa